Chief Executive Officer, Chief Financial Officer, Board Chairman
Mr. Ehrlich is a co-founder of Cellceutix and serves as Chief Financial Officer and Chief Executive Officer for the company. He also is Board Chairman. Mr. Ehrlich has over 25 years of executive leadership experience in building and managing emerging growth companies. Prior to joining Cellceutix, Mr. Ehrlich served as Chief Financial Officer and Director of Nanoviricides, a publicly-traded company developing nanotechnology-based anti-viral medicines. Mr. Ehrlich also served in various management roles—as CEO, President, CFO, Director—while at StatSure Diagnostic Systems, Inc., a diagnostic specialty firm with a focus on HIV testing. Mr. Ehrlich is a Certified Public Accountant and received a BBA degree from Bernard Baruch College of the City University of New York.
Arthur P. Bertolino, MD, PHD, MBA
President and Chief Medical Officer
Dr. Bertolino serves as President and Chief Medical Officer at Cellceutix. Dr. Bertolino is a leading pharmaceutical dermatology executive with over 15 years of domestic and global drug development and management experience. Previously, he was Vice President of Dermatology at Novartis, Vice President and Chief Medical Officer of Peplin, Inc., and Senior Director of Dermatology at Pfizer. Dr. Bertolino has authored over 50 abstracts, papers, and book chapters, and has been a regular on-air and in-print contributor to leading media companies. Dr. Bertolino received a BS (Chemistry/Biochemistry) degree from SUNY Stony Brook, an MD and PhD (Pharmacology) from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business.
Krishna Menon, PhD, DVM
Chief Scientific Officer, President of Research, and Board of Directors
Dr. Menon is a co-founder of Cellceutix, serving as Chief Scientific Officer, and Board Member. He is a leading pharmaceutical scientist with over 30 years of drug development experience in academia and industry. Prior to Cellceutix, Dr. Menon served at Eli Lilly as Group Leader, Cancer In Vivo Research and Clinical Development. While there, Dr. Menon played an integral role in lead selection and pre-clinical development of Gemzar and Alimta, two blockbuster oncology drugs. He was awarded Eli Lilly’s prestigious President’s Recognition Award. Earlier in his professional career, he held research scientist positions at Miles Laboratories and Dana Farber Cancer Research Institute. Dr. Menon is a trained veterinary surgeon (DVM) and holds a PhD (Pharmacology) from Kerala University.
Jane Harness, MP, MS
Vice President, Clinical Sciences and Portfolio Management
Ms. Harness is Vice President, Clinical Sciences and Portfolio Management, for Cellceutix. Ms. Harness has over 20 years in domestic and international clinical drug development experience. Before joining Cellceutix, she served as Vice President, Clinical Operations, at Revance Therapeutics. Prior, she was the Head of Clinical Sciences, Dermatology and ATI Translational Research, at Novartis Institutes for Biomedical Research. Across fifteen years at Pfizer, she held the following notable positions: Global Clinical Lead, Inflammation and Immunology; Early Clinical Lead, Dermatology; and Clinical Trial Head and Process Improvement Lead, Experimental Medicine. Ms. Harness received a BS and MP (Protein Biochemistry) degree from University of Leicester, and a MS (Clinical Pharmacology) from University of Aberdeen.
LaVonne Lang, MPH, DrPH
Vice President, Regulatory Affairs
Dr. Lang serves as Vice President of Regulatory Affairs for Cellceutix. She has over fifteen years of management experience in senior regulatory roles at various pharmaceutical and biotechnology companies. Most recently, Dr. Lang was an independent consultant on regulatory strategy, with a focus in biologics and dermatology. Prior, she was Head of Regulatory Affairs for Aastrom Biosciences, and before that served as Senior Director, Regulatory Affairs, for United BioSource/Medco. Across her eighteen years at Parke / Davis Pfizer, she assumed numerous roles, including: Associate Scientist, Safety Assessment; Senior Clinical Communications Specialist; Clinical Communications Director; and for a decade, Director, World Wide Regulatory Affairs. Dr. Lang received a BSN, a MPH (Environmental and Industrial Health: Toxicology), and a DrPH (Health Management and Policy) from The University of Michigan.